Severe neutropenia following infliximab treatment in a child with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages

  Sherlock, Mary ^a   Bandsma, Robert ^a   Ota, Kaede ^a   Kirby Allen, Melanie ^a   Griffiths, Anne ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; PREDNISONE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; BLOODY DIARRHEA; CASE REPORT; CHILD; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; MALE; NEUTROPENIA; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651327288     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21466     Document Type: Letter

References (8)

1. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508.
2. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133: 423-432.
3. Keisu M, Ekman E,. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol. 1992; 43: 215-218.
4. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-alpha agents. Ann NY Acad Sci. 2005; 1051: 559-569.
5. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008; 30: 523-529.
6. Favalli EG, Varenna M, Sinigaglia L,. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondylarthropathy. Clin Exp Rheumatol. 2005; 23: 247-250.
7. Rajakulendran S, Gadsby K, Allen D, et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006; 65: 1678-1679.
8. Montané E, Sallés M, Barriocanal A, et al. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol. 2007; 26: 1527-1529.